Literature DB >> 16711015

Expression of EGFR and LRIG-1 in human trigeminal neurinoma.

Zongqiang Xiong1, Yingguang Cao, Dongsheng Guo, Fei Ye, Ting Lei.   

Abstract

The expression of epidermal growth factor receptor (EGFR) and leucine-rich repeats and immunoglobulin-like domain 1 (LRIG-1) in human trigeminal neurinoma was investigated and their effect on the origination and development of trigeminal neurinoma, and the relationship between them was studied. By using immunohistochemistry with tissue chip, the expression of EGFR and LRIG-1 was detected in 23 cases of trigeminal neurinoma. It was found that in the 23 cases, the expression rate of EGFR was 21.74%, while that of the LRIG-1 was 78.26%. There was a negative correlation between them. It was suggested that LRIG-1 might inhibit the malignant differentiation and proliferation of the trigeminal neurinoma possibly by the negative feedback loop of EGFR.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16711015     DOI： 10.1007/bf02828046

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN： 1672-0733


  9 in total

1.  cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains.

Authors:  Y Suzuki; N Sato; M Tohyama; A Wanaka; T Takagi
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

2.  Cloning, characterization, and expression of human LIG1.

Authors:  J Nilsson; C Vallbo; D Guo; I Golovleva; B Hallberg; R Henriksson; H Hedman
Journal:  Biochem Biophys Res Commun       Date:  2001-06-29       Impact factor: 3.575

Review 3.  Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Authors:  A Besson; V W Yong
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  The Drosophila kekkon genes: novel members of both the leucine-rich repeat and immunoglobulin superfamilies expressed in the CNS.

Authors:  M Musacchio; N Perrimon
Journal:  Dev Biol       Date:  1996-08-25       Impact factor: 3.582

5.  Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.

Authors:  A Waha; A Baumann; H K Wolf; R Fimmers; J Neumann; D Kindermann; K Astrahantseff; I Blümcke; A von Deimling; U Schlegel
Journal:  J Neurosurg       Date:  1996-10       Impact factor: 5.115

6.  [Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4].

Authors:  Fei Ye; Dong-Sheng Guo; Hong-Quan Niu; Sheng-Zhong Tao; Yi-Bo Ou; Yun-Ping Lu; Ting Lei
Journal:  Ai Zheng       Date:  2004-10

7.  The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.

Authors:  Melanie B Laederich; Melanie Funes-Duran; Lily Yen; Ellen Ingalla; Xiuli Wu; Kermit L Carraway; Colleen Sweeney
Journal:  J Biol Chem       Date:  2004-09-01       Impact factor: 5.157

8.  LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.

Authors:  Gal Gur; Chanan Rubin; Menachem Katz; Ido Amit; Ami Citri; Jonas Nilsson; Ninette Amariglio; Roger Henriksson; Gideon Rechavi; Håkan Hedman; Ron Wides; Yosef Yarden
Journal:  EMBO J       Date:  2004-07-29       Impact factor: 11.598

9.  Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis.

Authors:  U Diedrich; J Lucius; E Baron; J Behnke; B Pabst; B Zoll
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849
  9 in total
  2 in total

1.  Effect of over-expressed LRIG3 on cell cycle and survival of glioma cells.

Authors:  Hongkuan Yang; Feng Mao; Huaqiu Zhang; Baofeng Wang; Feng Wan; Dongsheng Guo; Ting Lei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

2.  Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis.

Authors:  Victoria E Abraira; Takunori Satoh; Donna M Fekete; Lisa V Goodrich
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.